• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

筏、纳米颗粒与神经疾病

Rafts, Nanoparticles and Neural Disease.

作者信息

Gulati Vishal, Wallace Ron

机构信息

Ross University School of Medicine, Miami Beach Community Health Center, 11645 Biscayne Boulevard, North Miami, FL 33181, USA.

Department of Anthropology, University of Central Florida, Orlando, FL 32816, USA.

出版信息

Nanomaterials (Basel). 2012 Aug 6;2(3):217-250. doi: 10.3390/nano2030217.

DOI:10.3390/nano2030217
PMID:28348305
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5304588/
Abstract

This review examines the role of membrane rafts in neural disease as a rationale for drug targeting utilizing lipid-based nanoparticles. The article begins with an overview of methodological issues involving the existence, sizes, and lifetimes of rafts, and then examines raft function in the etiologies of three major neural diseases-epilepsy, Parkinson's disease, and Alzheimer's disease-selected as promising candidates for raft-based therapeutics. Raft-targeting drug delivery systems involving liposomes and solid lipid nanoparticles are then examined in detail.

摘要

本综述探讨了膜筏在神经疾病中的作用,以此作为利用脂质纳米颗粒进行药物靶向治疗的理论依据。文章首先概述了涉及膜筏的存在、大小和寿命的方法学问题,然后研究了膜筏在三种主要神经疾病(癫痫、帕金森病和阿尔茨海默病)病因中的作用,这三种疾病被选为基于膜筏治疗的有前景的候选对象。随后详细研究了涉及脂质体和固体脂质纳米颗粒的膜筏靶向给药系统。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c80e/5304588/e52187ed2cac/nanomaterials-02-00217-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c80e/5304588/6634d2a1b906/nanomaterials-02-00217-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c80e/5304588/e52187ed2cac/nanomaterials-02-00217-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c80e/5304588/6634d2a1b906/nanomaterials-02-00217-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c80e/5304588/e52187ed2cac/nanomaterials-02-00217-g002.jpg

相似文献

1
Rafts, Nanoparticles and Neural Disease.筏、纳米颗粒与神经疾病
Nanomaterials (Basel). 2012 Aug 6;2(3):217-250. doi: 10.3390/nano2030217.
2
Anomalies occurring in lipid profiles and protein distribution in frontal cortex lipid rafts in dementia with Lewy bodies disclose neurochemical traits partially shared by Alzheimer's and Parkinson's diseases.路易体痴呆患者额叶皮质脂筏中脂质谱和蛋白质分布出现的异常揭示了阿尔茨海默病和帕金森病部分共有的神经化学特征。
Neurobiol Aging. 2017 Jan;49:52-59. doi: 10.1016/j.neurobiolaging.2016.08.027. Epub 2016 Sep 6.
3
Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems.通过药物递送系统治疗阿尔茨海默病和帕金森病的策略
Curr Med Chem. 2016;23(31):3618-3631. doi: 10.2174/0929867323666160824162401.
4
Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications.鞘磷脂与胆固醇:从膜生物物理和脂筏到潜在医学应用
Subcell Biochem. 2004;37:167-215. doi: 10.1007/978-1-4757-5806-1_5.
5
Amyloid-β Interactions with Lipid Rafts in Biomimetic Systems: A Review of Laboratory Methods.生物仿系统中淀粉样蛋白-β与脂筏的相互作用:实验室方法综述。
Methods Mol Biol. 2021;2187:47-86. doi: 10.1007/978-1-0716-0814-2_4.
6
Nanomedicine against Alzheimer's and Parkinson's Disease.纳米医学治疗阿尔茨海默病和帕金森病。
Curr Pharm Des. 2021;27(12):1507-1545. doi: 10.2174/1381612826666201021140904.
7
Lipid rafts in neurodegeneration and neuroprotection.神经退行性变与神经保护中的脂筏
Mol Neurobiol. 2014 Aug;50(1):130-48. doi: 10.1007/s12035-013-8614-4. Epub 2013 Dec 22.
8
Lipid Raft Size and Lipid Mobility in Non-raft Domains Increase during Aging and Are Exacerbated in APP/PS1 Mice Model of Alzheimer's Disease. Predictions from an Agent-Based Mathematical Model.在衰老过程中,非筏区的脂筏大小和脂质流动性增加,在阿尔茨海默病的APP/PS1小鼠模型中加剧。基于主体的数学模型预测。
Front Physiol. 2016 Mar 15;7:90. doi: 10.3389/fphys.2016.00090. eCollection 2016.
9
Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling.脂筏与阿尔茨海默病:蛋白质-脂质相互作用及信号传导紊乱
Front Physiol. 2012 Jun 22;3:189. doi: 10.3389/fphys.2012.00189. eCollection 2012.
10
AmyP53 Prevents the Formation of Neurotoxic β-Amyloid Oligomers through an Unprecedent Mechanism of Interaction with Gangliosides: Insights for Alzheimer's Disease Therapy.AmyP53 通过与神经节苷脂相互作用的前所未有的机制来防止神经毒性 β-淀粉样寡聚物的形成:阿尔茨海默病治疗的新见解。
Int J Mol Sci. 2023 Jan 16;24(2):1760. doi: 10.3390/ijms24021760.

本文引用的文献

1
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.系统给予 TUSC2(FUS1)-纳米颗粒介导的功能基因转移的人体 I 期临床试验。
PLoS One. 2012;7(4):e34833. doi: 10.1371/journal.pone.0034833. Epub 2012 Apr 25.
2
Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles.利用聚合物纳米粒的物理和化学策略进行治疗性递药。
Pharmacol Rev. 2012 Jul;64(3):505-19. doi: 10.1124/pr.111.005363. Epub 2012 Apr 27.
3
Uses of single-particle tracking in living cells.
单粒子追踪在活细胞中的应用。
Drug Discov Ther. 2010 Apr;4(2):62-9.
4
2012 Alzheimer's disease facts and figures.2012 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2012;8(2):131-68. doi: 10.1016/j.jalz.2012.02.001.
5
Direct evidence of lipid rafts by in situ atomic force microscopy.原位原子力显微镜直接观察脂筏。
Small. 2012 Apr 23;8(8):1243-50. doi: 10.1002/smll.201102183. Epub 2012 Feb 20.
6
Lipid-based nanocarriers for CNS-targeted drug delivery.用于中枢神经系统靶向给药的脂质基纳米载体。
Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):71-86. doi: 10.2174/157488912798842241.
7
Organically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivo.有机改性硅纳米颗粒具有生物相容性,并且可以在体内靶向神经元。
PLoS One. 2012;7(1):e29424. doi: 10.1371/journal.pone.0029424. Epub 2012 Jan 3.
8
The history of Parkinson's disease: early clinical descriptions and neurological therapies.帕金森病的历史:早期临床描述和神经治疗方法。
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a008862. doi: 10.1101/cshperspect.a008862.
9
Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents.用于高效磁共振成像对比剂的均一尺寸氧化铁纳米粒子的设计合成。
Chem Soc Rev. 2012 Apr 7;41(7):2575-89. doi: 10.1039/c1cs15248c. Epub 2011 Dec 2.
10
The NMDA receptor complex as a therapeutic target in epilepsy: a review.NMDA 受体复合物作为癫痫治疗靶点的研究进展。
Epilepsy Behav. 2011 Dec;22(4):617-40. doi: 10.1016/j.yebeh.2011.07.024. Epub 2011 Nov 4.